To show the relevance of network centrality and therapeutic targets, Figure 2 included immunotherapy targets that are either used for treating NSCLC patients (including PD1, PDL1, and CTLA4) or showed promising results in phase I/II clinical trials (CD27). Here, CD27 is linked to non-small cell lung carcinoma.